NASDAQ · CLBT
Cellebrite DI financials
$10.93−1.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $475.7M | $401.2M | $325.1M | $270.7M | $246.2M |
| Gross profit | $400.5M | $338.6M | $271.9M | $219.9M | $203.7M |
| Gross margin | 84.2% | 84.4% | 83.6% | 81.3% | 82.7% |
| Operating income | $66.5M | $56.9M | $33.2M | $1.0M | $13.8M |
| Net income | $78.3M | -$283.0M | -$81.1M | $116.1M | $70.4M |
| Net margin | 16.5% | −70.5% | −24.9% | 42.9% | 28.6% |
| Diluted EPS | $0.31 | $-1.35 | $-0.43 | $0.59 | $0.44 |
| EBITDA | $78.3M | $67.5M | $43.2M | $10.2M | $20.8M |
| Operating cash flow | $173.5M | $132.2M | $102.1M | $20.6M | $36.1M |
| Free cash flow | $160.3M | $123.6M | $96.8M | $13.7M | $30.9M |
| Diluted shares | 249.9M | 209.5M | 190.2M | 195.4M | 161.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $124.5M | $191.7M | $189.5M | $87.6M | $146.0M |
| Short-term investments | $151.5M | $101.8M | $38.7M | $44.6M | $35.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $938.9M | $690.6M | $532.9M | $403.3M | $339.8M |
| Total liabilities | $454.5M | $354.5M | $498.7M | $329.4M | $413.1M |
| Shareholders' equity | $484.3M | $336.0M | $34.2M | $73.9M | -$73.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology